01—Abstract
Summary
Summary of the 8-K filed September 22, 2026. Cited figures are marked; the original filing is the authoritative source.
On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 milliona aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million issued under the initial purchasers' option.
The Company received net proceeds of approximately $1,471.1 millionb after discounts, commissions and estimated offering expenses. The notes were sold under Section 4(a)(2) of the Securities Act and Rule 144A to qualified institutional buyers, and are unsecured obligations that rank senior to subordinated indebtedness and equally with existing unsubordinated liabilities. Interest is payable semi-annually on April 1 and October 1, beginning April 1, 2027.
The Company used approximately $187.5 millionc of the proceeds to fund capped call transactions, which are intended to reduce potential dilution on conversion, subject to a cap price of approximately $208.39 per share. It also expects to use part of the proceeds to repurchase $151.7 million of its 0.25% convertible notes due 2027 and $220.0 million of its 1.00% convertible notes due 2028, for total repurchase costs of approximately $217.0 million and $435.5 million, respectively, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases.
The notes have an initial conversion rate of 7.1509 shares per $1,000d principal amount, equivalent to a conversion price of approximately $139.84 per share, and the Company may settle conversions in cash, shares, or a combination at its election. Conversion is permitted under specified conditions, including a share price test of 130% of the conversion price and at any time from April 1, 2033 until shortly before maturity.
The notes are redeemable at the Company's option on or after October 7, 2030 subject to a share price condition, and a cleanup redemption is available if less than $100.0 million remains outstanding. Holders may require repurchase at par plus accrued interest upon a fundamental change.
02—Key points
Key Highlights
- Issued $1,500.0 million of 1.50% Convertible Senior Notes due 2033, including the $200.0 million option exercised by initial purchasers, with net proceeds of approximately $1,471.1 million.
- Initial conversion price of approximately $139.84 per share (conversion rate of 7.1509 shares per $1,000 principal), with a maximum of 13,676,100 shares potentially issuable under the maximum conversion rate of 9.1174.
- Approximately $187.5 million of proceeds used to fund capped call transactions with a cap price of approximately $208.39 per share, representing a premium of approximately 90.0% over the September 17, 2026 closing price.
- Plans to repurchase $151.7 million of 0.25% convertible notes due 2027 (total cost approximately $217.0 million) and $220.0 million of 1.00% convertible notes due 2028 (total cost approximately $435.5 million), including accrued interest.
- Notes are unsecured, structurally subordinated to subsidiary liabilities, and include events of default tied to indebtedness of at least $50.0 million.
- Provisional redemption available on or after October 7, 2030 subject to a 130% share price test; cleanup redemption available if less than $100.0 million remains outstanding.
- Notes sold in a private offering under Section 4(a)(2) and Rule 144A, so the notes and underlying shares are unregistered.
03—Questions
Frequently Asked Questions
How much capital did Halozyme raise and how will it be used?
The Company received net proceeds of approximately $1,471.1 million. It used about $187.5 million for capped call transactions and expects to use a portion to repurchase $151.7 million of 2027 Notes and $220.0 million of 2028 Notes, with the remainder for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases.
At what share price would the notes convert?
The initial conversion rate is 7.1509 shares per $1,000 principal amount, equivalent to a conversion price of approximately $139.84 per share. The conversion rate is subject to adjustment and does not account for accrued or unpaid interest.
What do the capped call transactions do for shareholders?
The capped call transactions are expected generally to reduce potential dilution to common stockholders upon conversion, or offset cash payments above principal, subject to a cap price initially of approximately $208.39 per share. They are separate from the notes, and noteholders have no rights under them.
When can holders convert or the Company redeem the notes?
Holders may convert under specified conditions, including if the stock price exceeds 130% of the conversion price for at least five trading days in a 20-day period, and at any time from April 1, 2033 until shortly before maturity. The Company may redeem the notes on or after October 7, 2030 if the stock price test is met, and may redeem all outstanding notes if less than $100.0 million remains outstanding.
What protections do noteholders have if a change of control occurs?
Upon a fundamental change, holders may require the Company to repurchase their notes for cash at 100% of principal plus accrued and unpaid interest. In some cases, the Company will increase the conversion rate for holders who convert in connection with a make-whole fundamental change.
04—Continue